Search results
Author(s):
Paulus Kirchhof
Added:
7 months ago
ESC 2023 — Prof Paulus Kirchhof (University Heart & Vascular Center Hamburg, DE) discusses the findings of the NOAH-AFNET 6 trial (NCT02618577).
NOAH-AFNET 6 (Atrial Fibrillation Network, Daiichi Sankyo Europe) was an investigator-initiated, prospective, randomised trial aiming to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy in stroke prevention,…
View more
Author(s):
Duk-Woo Park
Added:
1 year ago
In this short interview, Dr Duk-Woo Park (Asan Medical Center, KR) discusses the findings from the ADAPT-TAVR Randomized Clinical Trial (NCT03284827).
The trial investigated Edoxaban versus dual antiplatelet therapy for leaflet thrombosis and cerebral thromboembolism after TAVR.
Presented first at ACC.22, ADAPT-TAVR shows that the overall incidence of leaflet thrombosis on CT scans was less…
View more
Author(s):
Dhanunjaya Lakkireddy
Added:
2 years ago
Dr Dhanunjaya Lakkireddy (Kansas City Heart Rhythm Institute, Overland Park, KS, US) sits down to discuss the findings of the STROKE-VT Trial, which investigated the use of aipaxaban in reducing blood clots and stroke risk after an ablation procedure.
Questions:
1. Please summarise the aim, study design and endpoints?
2. What were your major findings?
3. What further research is required?
4…
View more
Author(s):
Despoina-Rafailia Benetou
,
Panayotis K Vlachakis
,
Charalampos Varlamos
,
et al
Added:
2 years ago
Author(s):
Debra Green
,
Jack E Ansell
,
Stephan Moll
Added:
3 years ago
Oral anticoagulants are one of the most common causes of drug-induced adverse events.1 Expert dose management, which keeps the patient within a narrow therapeutic international normalized range (INR), is required to avoid adverse events and optimize therapy. Anticoagulation clinic (ACC) management has been shown to improve outcomes compared with the routine management provided by physicians,2 but…
View more
Author(s):
George D Dangas
Added:
2 years ago
In this short video, Dr George Dangas (Mount Sinai Hospital, New York, NY, US) shares the findings from the ENVISAGE-TAVI AF hot line trial presented at ESC Congress 2021.
ENVISAGE-TAVI AF (Daiichi-Sankyo) compared the safety and efficacy of the DOAC edoxaban with VKAs (warfarin and its analogues) in atrial fibrillation patients with an indication for oral anticoagulation after successful TAVI.
…
View more
Author(s):
Stefan H Hohnloser
Added:
3 years ago
Atrial fibrillation (AF) is the most common cardiac arrhythmia, and is associated with a five-fold increase in the risk of stroke and embolism.1 Oral anticoagulation (OAC) with warfarin reduces stroke by two-thirds compared with no treatment.1–3 Compared with aspirin, OAC reduces the risk of stroke by 45% and reduces cardiovascular events by 29%.4 However, it increases the risk of major bleeding…
View more
Carlos Morillo
Author
Author(s):
Mirvat Alasnag
,
Waqar Ahmed
,
Ibrahim Al-Nasser
,
et al
Added:
2 years ago